GlassScriptPhysician profile
Michael Castillo
NPI 1407389844
$2,090.64
in general payments reported to CMS, 2019-2025
13 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2022: $381 · 2023: $385 · 2024: $199 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399 · Education: $93.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.12 |
| Education | $93.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.74 | 2022-2025 | Skyrizi |
| Madrigal Pharmaceuticals | $235.65 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $180.17 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $134.57 | 2023 | Terlivaz |
| Sanofi-Aventis U.S. LLC | $132.92 | 2019 | |
| Boston Scientific Corporation | $106.63 | 2025 | Cre Pro, General - Polypectomy |
| Takeda Pharmaceuticals U.S.A., INC. | $95.91 | 2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $83.59 | 2019 | |
| Janssen Biotech, INC. | $82.10 | 2024-2025 | Tremfya |
| Biocon Biologics INC | $50.39 | 2025 | Yesintek |
| Daiichi Sankyo INC. | $47.81 | 2025 | Injectafer |
| Novo Nordisk INC | $47.56 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $24.60 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.